Last updated: 18 July 2019 at 4:04pm EST

Dr. Khursheed Anwer M.B.A., Ph.D. Net Worth



Dr. Khursheed Anwer M.B.A., Ph.D. biography

Dr. Khursheed Anwer M.B.A., Ph.D. is the Exec. VP & Chief Scientific Officer at Imunon Inc.

What is the salary of Dr D?

As the Exec. VP & Chief Scientific Officer of Imunon Inc, the total compensation of Dr D at Imunon Inc is $484,749. There are 6 executives at Imunon Inc getting paid more, with Michael Tardugno having the highest compensation of $1,694,790.



How old is Dr D?

Dr D is 61, he's been the Exec. VP & Chief Scientific Officer of Imunon Inc since . There are 9 older and 4 younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.

What's Dr D's mailing address?

Khursheed's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.

Insiders trading at Imunon Inc

Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link, and Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.



What does Imunon Inc do?

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.



What does Imunon Inc's logo look like?

Imunon Inc logo

Imunon Inc executives and stock owners

Imunon Inc executives and other stock owners filed with the SEC include: